Associations between XRCC3 Thr241Met polymorphisms and breast cancer risk: systematic-review and meta-analysis of 55 case-control studies

• Published in: BMC medical genetics Vol. 20; no. 1; p. 79
• Main Authors: Dashti, Sepideh, Taherian-Esfahani, Zahra, Keshtkar, Abbasali, Ghafouri-Fard, Soudeh
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 10-05-2019; BioMed Central; BMC
• Subjects: Biotechnology; Breast Cancer; Breast Neoplasms - genetics; Cancer research; Cells (Biology); Disease susceptibility; DNA-Binding Proteins - chemistry; DNA-Binding Proteins - genetics; Female; Future predictions; Gene polymorphism; Genes; Genetic aspects; Genetic polymorphisms; Genetic Predisposition to Disease; Genetic research; Health aspects; Health risk assessment; Heredity; Homologous Recombination; Hormone replacement therapy; Humans; Malignancy; Mammalian cells; Meta-analysis; Methionine - genetics; Neoplasm; Polymorphism, Single Nucleotide; Preservation; Risk factors; Single nucleotide polymorphism; Single nucleotide polymorphisms; Studies; Systematic review; Threonine - genetics; Tumors; Womens health; Neoplasm; Single nucleotide polymorphism; Breast Cancer; Genes
• ISSN: 1471-2350; 1471-2350
• DOI: 10.1186/s12881-019-0809-8

The X-ray repair cross-complementing group 3 (XRCC3) is an efficient component of homologous recombination and is required for the preservation of chromosomal integrity in mammalian cells. The association between Thr241Met single-nucleotide polymorphism (SNP) in this gene and susceptibility to breast cancer has been assessed in several studies. Yet, reports are controversial. The present meta-analysis has been designed to identify whether this SNP is associated with susceptibility to breast cancer.
We performed a systematic review and meta-analysis for retrieving the case-control studies on the associations between T241 M SNP and the risk of breast cancer. Crude odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to verify the association in dominant, recessive, and homozygote inheritance models.
We included 55 studies containing 30,966 sporadic breast cancer cases, 1174 familial breast cancer cases and 32,890 controls in the meta-analysis. In crude analyses, no association was detected between the mentioned SNP and breast cancer risk in recessive, homozygote or dominant models. However, ethnic based analysis showed that in sporadic breast cancer, the SNP was associated with breast cancer risk in Arab populations in homozygous (OR (95% CI) = 3.649 (2.029-6.563), p = 0.0001) and recessive models (OR (95% CI) = 4.092 (1.806-9.271), p = 0.001). The association was significant in Asian population in dominant model (OR (95% CI) = 1.296, p = 0.029). However, the associations was significant in familial breast cancer in mixed ethnic-based subgroup in homozygote and recessive models (OR (95% CI) = 0.451 (0.309-0.659), p = 0.0001, OR (95% CI) = 0.462 (0.298-0.716), p = 0.001 respectively).
Taken together, our results in a large sample of both sporadic and familial cases of breast cancer showed insignificant role of Thr241Met in the pathogenesis of this type of malignancy. Such results were more conclusive in sporadic cases. In familial cases, future studies are needed to verify our results.